Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Easton Pharmaceuticals Announces Development of a Blockchain and Cryptocurrency Initiative

Posted on: 21 Mar 18

TORONTO, ON, March 21, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals, Inc. (OTC: EAPH), announces it has initiated discussions for the development of a blockchain platform and cryptocurrency that will streamline the supply chain of medicinal / recreational marijuana.

In the company’s continuing search for new products, technologies, and other lucrative business opportunities in other industries towards enhancing shareholder value, Easton Pharmaceuticals is planning to launch a Blockchain based platform for medicinal marijuana to streamline the supply chain, improve efficiency, provide transparency and simplify cross border transactions from Licensed Producers (LP’s), distributors, dispensaries, pharmaceutical companies and various government agencies right down to approved end users. 

The solution will be built on the platform of an industry leader in Blockchain technology with future plans of utilizing digital identity solutions over the developed network to facilitate secure and accurate end user transactions. 

Participating users will be able to buy, sell and pay for product with cryptocurrency. This platform will help millions of users around the world in a secure environment. This initiative may involve the participation of current Easton partners in the medical / recreational marijuana industry or other future potential partners Easton has initiated discussions with.

More information will be announced in the coming weeks as development and roll out plans are finalized as well as updates to the anticipated commencement of Alliance Group aggregate operations and to its recently executed BAYER sub-distribution agreement.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica and together own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic / treatment products and two generic cancer drugs. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. Easton has closed on an agreement to acquire a 50% ownership stake on a 135 acre property located in Georgina Township and 2 businesses that includes medical / recreational marijuana and aggregate.

For More Information On Easton Visit:

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

For More Information Visit:

CONTACT: Contact: Evan Karras / CEO / President  Tel: +1(416) 619-0291 Tel: +1(347) 284-0192 Email: info@eastonpharmaceuticalsinc.comGlobeNewswire

Last updated on: 22/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.